CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin

Epidemiological studies suggest that food rich in quercetin and naringin may protect against certain types of lung cancer, and that genotype dependent inhibition of cytochrome P450 1A1 (CYP1A1)-mediated bioactivation of procarcinogens could be the underlying mechanism. We studied the inhibitory effects of quercetin and naringin on the terminal bioactivation step of benzo[a]pyrene (B[a]P), a member of the major class of lung carcinogens. This reaction (epoxidation of (+/-)-trans-7,8-dihydro-7,8-dihydroxy-B[a]P to the ultimate carcinogenic product, (+/-)-B[a]P-r-7,t-8-dihydrodiol-t-9,10-epoxide (diolepoxide 2)) was examined using three of the most common allelic variants of human CYP1A1, namely wild-type CYP1A1.1, CYP1A1.2, and CYP1A1.4. Quercetin potently inhibited diolepoxide 2 formation by all CYP1A1 types with IC(50) values between 1.6 and 7.0 microM. The differences between the wild-type enzyme and the variants were statistically highly significant (P < 0.01). Enzyme kinetics revealed quercetin as a mixed-type inhibitor of CYP1A1.1, CYP1A1.2, and CYP1A1.4 with K(i) values of 2.0, 6.4, and 9.3 microM, respectively. Naringin inhibited diolepoxide 2 formation only slightly. Our data support the hypothesis that quercetin may have a stronger chemopreventive effect in individuals carrying wild-type compared with variant CYP1A1 genes. Future studies should consider the influence of P450 polymorphisms on both procarcinogen activation and its inhibition to facilitate the development of genotype-specific chemoprevention regimes.     

Inhibitory effect of Phenethyl Isothiocyanate Against Benzo[a] Pyrene-Induced Rise in CYP1A1 mRNA and Apoprotein Levels as its Chemopreventive Properties

Background: Phenethyl isothiocyanate (PEITC), the most comprehensively studied aromatic isothiocyanate,has been shown to act as an anti-cancer agent mainly through modulation of biotransformation enzymesresponsible for metabolizing carcinogens in the human body. Humans are often exposed to carcinogenic factors,some of which through the diet, such as polycyclic aromatic hydrocarbon benzo[a]pyrene via the consumptionof over-cooked meats. Inhibition of the enzymes responsible for the bioactivation of this carcinogen, for exampleCYP1A1, the major enzyme required for polycyclic aromatic hydrocarbons (PAHs) bioactivation, is recognizedas a chemoprevention strategy. Objective: To evaluate the inhibitory effects of PEITC against benzo[a]pyreneinducedrise in rat liver CYP1A1 mRNA and apoprotein levels. Materials and Methods: Precision cut rat liverslices were treated with benzo[a]pyrene at 1 and 5 μM in the presence of PEITC (1-25 μM) for 24 hours, followedby determination of CYP1A1 mRNA and apoprotein levels using quantitative polymerase chain reaction andimmunoblotting. Results: Findings revealed that PEITC inhibited benzo[a]pyrene-induced rise in rat liverCYP1A1 mRNA in a dose-dependent manner as well as the apoprotein levels of CYP1A. Conclusions: It wasdemonstrated that PEITC can directly inhibit the bioactivation of benzo[a]pyrene, indicating chemopreventivepotential.     

Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)

2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) carcinogenesis is initiated by N(2)-hydroxylation, mediated by several cytochromes P450, including CYP1A1. However, the role of CYP1A1 in PhIP metabolic activation in vivo is unclear. In this study, Cyp1a1-null and wild-type (WT) mice were used to investigate the potential role of CYP1A1 in PhIP metabolic activation in vivo. PhIP N(2)-hydroxylation was actively catalyzed by lung homogenates of WT mice, at a rate of 14.9 +/- 5.0 pmol/min/g tissue, but <1 pmol/min/g tissue in stomach and small intestine, and almost undetectable in mammary gland and colon. PhIP N(2)-hydroxylation catalyzed by lung homogenates of Cyp1a1-null mice was approximately 10-fold lower than that of WT mice. In contrast, PhIP N(2)-hydroxylation activity in lung homogenates of Cyp1a2-null versus WT mice was not decreased. Pretreatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin increased lung Cyp1a1 mRNA and lung homogenate PhIP N(2)-hydroxylase activity approximately 50-fold in WT mice, where the activity was substantially inhibited (70%) by monoclonal antibodies against CYP1A1. In vivo, 30 min after oral treatment with PhIP, PhIP levels in lung were similar to those in liver. After a single dose of 0.1 mg/kg [(14)C]PhIP, lung PhIP-DNA adduct levels in Cyp1a1-null mice, but not in Cyp1a2-null mice, were significantly lower (P = 0.0028) than in WT mice. These results reveal that mouse lung has basal and inducible PhIP N(2)-hydroxylase activity predominantly catalyzed by CYP1A1. Because of the high inducibility of human CYP1A1, especially in cigarette smokers, the role of lung CYP1A1 in PhIP carcinogenesis should be considered. (237 words).     

Induction of CYP1A1 gene expression in H4-II-E rat hepatoma cells by benzo[e]pyrene.

In the rat, expression of the CYP1A1 gene is closely associated with arylhydrocarbon hydroxylase (AHH) enzyme activity. AHH is an inducile enzyme activity known to play an important role in the bioactivation of polycyclic aromatic hydrocarbons (PAHs) to mutagenic and carcinogenic metabolites. PAH-induced expression of the CYP1A1 gene appears to be regulated by several trans-acting factors, including the Ah receptor and the 4S PAH-binding protein. In this study, we used the PAH isomers benzo[a]pyrene (BaP) and benzo[e]pyrene (BeP) to further evaluate the role of the 4S PAH-binding protein in induction of the CYP1A1 gene in H4-II-E rat hepatoma cells. Although BaP is believed to bind to both the Ah receptor and the 4S protein, BeP has been reported to bind exclusively to the 4S protein. The results of the study presented here indicate that BaP and BeP induce the expression of the CYP1A1 gene, as measured by ethoxyresorufin O-deethylase (EROD) activity, in a concentration-dependent manner. However, BaP is about 25 times as potent as BeP in inducing EROD activity in these cells. Slot-blot analysis of total RNA isolated from these cells indicated that BeP, BaP, and 3-methylcholanthrene increased the level of CYP1A1 mRNA expression. Sucrose-gradient analysis of BeP binding activity indicated that BeP bound with high affinity to the 4S PAH-binding protein, but not to the Ah receptor. These results suggest that the 4S protein may play a role in the PAH-induced expression of the CYP1A1 gene in rat H4-II-E cells.     

Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo[a]pyrene

Resveratrol inhibits PAH bioactivation through reduced expression of the CYP1A1 and CYP1B1 genes in human bronchial epithelial cells. Ad libitum access to a diet containing resveratrol showed no effect on benzo[a]pyrene-induced lung tumorigenesis in A/J mice. Also, resveratrol did not change CYP1A1 and CYP1B1 gene expression or benzo[a]pyrene protein adduct levels in the lung tissue. The lack of chemopreventive activity may have been caused by insufficient concentrations or nonreactive forms of resveratrol in the lungs.     

Localization of CYP1A1 mRNA in human lung by in situ hybridization: Comparison with immunohistochemical findings

Cytochrome P4501A1 (CYP1A1) is involved in the bioactivation of polycyclic aromatic hydrocarbons into their reactive epoxide metabolites. CYP1A1 is considered to be important with regard to individual susceptibility to lung cancer since phenotypic and genotypic polymorphisms of CYP1A1 have been associated with an increased risk of lung cancer in a number of studies. We examined here the expression and localization of CYP1A1 mRNA in human lung tissue using in situhybridization with a CYP1A1-specific RNA probe. A centrilobular expression of CYP1A1 mRNA was observed in the peripheral lung. The expression was intense in bronchiolar epithelium of peripheral lung, especially in terminal cuboidal epithelium. Type II alveolar epithelial cells were also intensely labelled. Type I alveolar epithelial cells and vascular epithelium exhibited binding but the hybridization signals were less intense. Our results are in good agreement with our previous work on immunohistochemical localization of CYP1A protein, in which we used the 1-7-1 MAb that recognizes both CYP1A1 and CYP1A2. In serial sections analyzed with in situhybridization and immunohistochemistry, a similar distribution of CYP1A1 mRNA and CYP1A protein was observed. CYP1A1 mRNA is thus expressed in human lungs and the expression is particularly intense in the cell types involved in the development of peripheral lung cancers. Int. J. Cancer 77:33–39, 1998.© 1998 Wiley-Liss, Inc.     

Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP

Mono-specific antibodies targeted to human CYP1A1 and CYP1A2have been produced by immunizing rabbits with protein conjugatesof short synthetic peptides corresponding to residues 290–297and 284–296 respectively, of these enzymes. The antibodytargeted to CYP1A1 bound in immunoblotting to the recombinantprotein expressed in yeast but did not bind to any human hepaticmicrosomal protein, whereas the antibody targeted to CYP1A2bound only to this enzyme in immunoblotting of human hepaticmicrosomal fractions and did not recognize recombinant humanCYP1A1. The intensity of hepatic microsomal CYP1A2 immunoreactivity(n = 5) correlated significantly with a number of activitiescharacteristic of this enzyme: phenacetin O-deethylase (POD),ethoxyresorufin O-deethylase (EROD) and methoxyresorufin O-demethylaseactivities and the ability to activate the dietary carcinogen2-amino-3, 8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), to amutagen. The anti-CYP1A2 anti-peptide antibody consistentlyinhibited both POD and EROD activities, but inhibition was incomplete(28%). In view of the known (>90%) contribution of CYP1A2to these activities and the correlation with antibody binding,this is consonant with an epitope for the anti-CYP1A2 anti-peptideantibody that forms the edge of a functionally important proinhibitorysurface region previously identified in rat cytochromes CYP1A.CYP1A2 immunoreactivity determined by immunoblotting correlatedsignificantly with the ability of human hepatic microsomal fractionsto activate 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine(PhIP), another dietary carcinogen, to a mutagen. It is concludedthat CYP1A1 is absent from human liver and that CYP1A2 is likelyto be a major catalyst in the hepatic activation of PhIP.     

Polycyclic aromatic hydrocarbon-DNA adducts in human placenta and modulation by CYP1A1 induction and genotype

This study investigated the relationship in human placenta between polycyclic aromatic hydrocabon (PAH)-DNA adduct levels and two biomarkers of cytochrome P4501A1 (CYP1A1): gene induction evidenced by CYP1A1 mRNA, and a genetic polymorphism, the CYP1A1 MspI RFLP. CYP1A1 codes for an inducible enzyme system that catalyzes the bioactivation of PAHs. Prior research found a high correlation in human lung tissue between CYP1A1 activity and DNA damage from PAHs. The CYP1A1 Mspi RFLP has been linked in some studies to risk of lung cancer. The relationships in human placenta between DNA damage, CYP1A1 activity and genotype have not been well characterized and may be relevant to risks from transplacental PAH exposure. The study cohort consisted of 70 newborns from Krakow, Poland, a city with elevated air pollution, and 90 newborns from nearby Limanowa, an area with lower air pollution but greater indoor coal use. Contrary to results seen previously in lung tissue, CYP1A1 mRNA was not significantly correlated with PAH-DNA adduct levels in the placenta. Smoking (self-reported maternal and infant plasma cotinine) was significantly associated with CYP1A1 mRNA levels (P < 0.01), but not with PAH-DNA adduct levels. Placental PAH- DNA adduct levels were significantly higher in infants with the CYP1A1 MspI restriction site compared with infants without the restriction site (P < 0.01), implicating a genetic factor in inter-individual variation in DNA damage in human placenta. Further studies are needed to determine the relevance of this finding to risk of transplacental carcinogenesis.      

Functional evaluation of novel single nucleotide polymorphisms and haplotypes in the promoter regions of CYP1B1 and CYP1A1 genes

Interindividual variation in the expression of the carcinogen- and estrogen-metabolizing enzymes cytochrome P4501B1 and 1A1 (CYP1B1 and CYP1A1) has been detected in human lung. To search for polymorphisms with functional consequences for CYP1B1 and CYP1A1 gene expression, we examined 1.5 kb of the promoter region of each gene. Genomic DNA from 21 Caucasian individuals was amplified by polymerase chain reaction (PCR) for direct cycle sequencing. Eight single nucleotide polymorphisms (SNPs) for CYP1B1 and 13 SNPs for CYP1A1 were found. The majority of polymorphisms occurred as multiSNP combinations for individual subjects. The wild-type sequences were cloned into a luciferase reporter construct. The most frequent polymorphisms were then recreated by iterative site-directed mutagenesis, replicating single polymorphisms and multiSNP combinations. These wild-type and variant constructs were functionally evaluated in transient transfection experiments employing exposures to either the index polycyclic aromatic hydrocarbon (PAH) inducer benzo[a]pyrene (B[a]P), a composite mixture of cigarette smoke extract (CSE), or the repressor chemopreventive agent trans-3,4,5-trihydroxystilbene (reseveratrol). Results indicated that all wild-type and variant constructs responded in qualitatively concordant fashion to the inducers and to the repressor. The CYP1B1 haplotypes and the majority of CYP1A1 haplotypes were shown to have no functional consequence, as compared to those of the wild-type promoter sequences. Two constructs of composite polymorphisms of CYP1A1 appeared to result in a statistically significant increase in basal promoter activity (1.38- and 1.50-fold, respectively), but the degree of functional impact was judged unlikely to be biologically important in vivo. We conclude that the observed promoter region polymorphisms in these genes are common, but are of unclear functional consequence.     

Differential effects of oltipraz on CYP1A and CYP2B in rat lung

Oltipraz (OPZ) is a potent chemopreventive agent against chemically-induced carcinogenesis in several animal models. It affects the expression and/or activity of xenobiotic-metabolizing enzymes and its effects are altered in the course of inflammation in liver. The present study was undertaken to analyse the effect of OPZ alone or in combination with Escherichia coli lipopolysaccharide (LPS) on the expression and activities of glutathione S-transferases (GSTs) and cytochrome P450 (CYPs) in rat lung and kidney. Male Wistar rats were fed a diet containing OPZ for 1-5 days. LPS was injected 24 h before the end of OPZ treatment (from 48 to 72 h). Total GST activity, measured using 1-chloro-2,4-dinitrobenzene as a substrate, increased slightly in both lung and kidney during OPZ treatment. As previously demonstrated in the liver, OPZ induced rat GSTP1 in both kidney and lung and this effect was totally (kidney) or partially (lung) inhibited by co-treatment with LPS. CYP1A expression and activity were strongly increased in both tissues 24 h after starting OPZ treatment and maintained for 5 days. This increase was suppressed during the acute-phase response to endotoxin. OPZ has no effect on CYP2B1 mRNA expression in the lung, but it dramatically decreased the amount and activity of the corresponding apoprotein. The OPZ-dependent decrease in the CYP2B1 apoprotein was abolished and its corresponding activity partially reversed during LPS treatment. In reconstitution experiments using cytosol from OPZ-treated or control rat lungs and microsomal fractions, CYP2B1 apoprotein was rapidly degraded in the presence of cytosol from treated rats. This effect was partially reversed in the presence of MG132, a proteasome inhibitor. These observations support the conclusion that the decrease of CYP2B1 by OPZ involves proteasome-dependent degradation and represents a new mechanism of regulation by this compound.     

Effect of cigarette smoke on CYP1A1, CYP1A2 and CYP2B1/2 of nasal mucosae in F344 rats

Enzymes of the nasal tissue, one of the first tissues to contact inhaled toxicants, are relatively resistant to induction by traditional inducers. Because tobacco smoke has been shown to induce cytochrome P450 1A1 (CYP1A1) in rat and human lung tissue, we hypothesized that it would also alter levels of xenobiotic-metabolizing enzymes in nasal mucosae. In the present study, the effect of mainstream cigarette smoke (MCS) on nasal CYP1A1, CYP1A2 and CYP2B1/2 was explored. Four groups of 30 F344 rats were exposed to MCS (100 mg total particulate matter/m3) or filtered air for 2 or 8 weeks. Western analysis of microsomes from nasal tissue of MCS-exposed rats showed an induction of CYP1A1 in respiratory and olfactory mucosae, as well as liver, kidney and lung. Relative to controls, CYP1A2 levels increased slightly in the liver and olfactory mucosa. CYP2B1/2, which increased in the liver, appeared to decrease in upper and lower respiratory tissues. Little to no immunoreactivity with CYP1A1 antibody was observed in fixed nasal sections of control rats, yet intense immunoreactivity was seen in epithelia throughout the nasal cavity of MCS-exposed rats. Ethoxyresorufin O-deethylase activity (associated with CYP1A1/2) decreased approximately 2-fold in olfactory mucosa, but increased in non-nasal tissues of rats exposed to MCS. Methoxy- and pentoxyresorufin O-dealkylase activities (associated with CYP1A2 and CYP2B1/2, respectively) decreased in olfactory and respiratory mucosae, as well as lung (CYP2B1/2), yet increased in liver. These data suggest that xenobiotic-metabolizing enzymines of the nasal mucosae may be regulated differently than other tissues.      

Mutagenicity and CYP1A induction by azobenzenes correlates with their carcinogenicity

The genotoxicity of six azobenzenes was evaluated in the Amestest, in the presence of an activation system derived from Aroclor1254-treated rats. Moreover, the ability of these azobenzenesto induce rat hepatic CYP1A activities and apoprotein levels,and stimulate their own bioactivation to mutagens, was alsodetermined. In the presence of the Arodor 1254-activation system,o-aminoazotoluene and 3-methoxy-4-aminoazobenzene were potentmutagens, whereas 4-amino- azobenzene and 4-dlethylaininoazobenzenefailed to elicit a positive mutagenic response. A very weakmutagenic response was induced by 2-methyl-4-dimethylaininoazobenzeneand by azobenzene. o-Aminoazotoluene and 3-methoxy-4-amino-azobenzene were potent inducers of CYP1A activities and apoproteinlevels, whereas the remaining four compounds displayed eithervery weak or no induction capability. None of the azobenzenesstudied could induce its own activation to mutagens in the Amestest. All six azobenzenes displaced [ from the cytosolic Ahreceptor, with o-amlnoazotoluene and 3-methoxy-4-aminoazo- benzenebeing the most effective. A correlation appears to exist betweencarcinogenic activity of azobenzenes in the rat on one hand,and of their mutagenic potential and hepatic CYP1 inductionon the other. Possible mechanisms accounting for this relationshipare discussed.     

Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human

The activation of heterocyclic amines to mutagenic productsby hepatic microsomal fractions from cynomolgus monkey, marmosetmonkey and man was compared with the respective levels of cytochromeP450 enzymes CYP1A1 and CYP1A2. The rate of activation of 2-amino-3,8-dimethylidazo[4,5-fquinoxaline (MeIQx), 2-amino-3-methylidazo[4,5-fquino-line (IQ)and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) tomutagens by hepatic microsomal fraction from cynomolgus monkeywas very low. This was associated with a lack of constitutiveexpression of CYP1A1 and CYP1A2. In contrast, human hepaticmicrosomal fraction readily activates these heterocyclic aminesand this is associated with constitutive expression of CYP1A2.Treatment of cynomolgus monkey with 2,3,7,8-tetrachlorodibenzo-p-dioxin(TCDD) causes a very modest induction of CYP1A2, and a smallincrease in the activation of MeIQx and IQ. However, there wasmarked induction of CYP1A1 which was accompanied by > 10-foldincreases in PhIP activation and 7-ethoxyresorufin O-deethylase(EROD), 7-methoxyresorufin O-demethyiase (MROD) and aryl hydrocarbonhydroxylase activities. Following treatment of cynomolgus monkeywith 3-methylcholanthrene, induction of CYP1A1, but not CYP1A2,was evident. In untreated marmoset monkey the activations ofMeIQx and PhIP, as well as pbenacetin O-deethylase, EROD, MRODand aryl hydrocarbon hydroxylase activities, are similar tothose in man, although the activations of IQ and coumarin 7-hydroxylaseactivity are lower than in man. The presence of constitutiveCYP1A2, and the absence of CYP1A1, in the liver of this speciescorrespond to the situation in man. Treatment of marmoset monkeywith TCDD results in increased CYP1A2 levels (4-fold), accompaniedby proportional increases in the activation of MeIQx and IQand phenacetui O-deethylase, EROD and MROD activities. The activationof PhIP is increased disproportionately, by 8-fold, most likelydue to the activity of CYP1A1 which is also induced by TCDDin this species. Overall, the hepatic metabolism of heterocyclicamines by CYP1A enzymes in the untreated marmoset monkey resemblesthat in human more closely than that in the cynomolgus monkey.Therefore, marmoset monkey may be a more suitable model thanthe cynomolgus monkey for carcinogenicity studies involvingMeIQx and PhIP, but not IQ     

Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms.

There are numerous conflicting epidemiological studies addressing correlations between cytochrome P450 1A1 (CYP1A1) genetic polymorphisms and lung cancer susceptibility, with associations plausibly linked to alterations in carcinogen bioactivation. Similarly, correlations between aryl hydrocarbon receptor gene (AHR) codon 554 genotype and CYP1A1 inducibility are controversial. The objective of this study was to determine whether smoking status, and CYP1A1, AHR, and glutathione S-transferase M1 gene (GSTM1) polymorphisms correlate with altered CYP1A1 activities. Lung microsomal CYP1A1-catalyzed 7-ethoxyresorufin O-dealkylation (EROD) activities were much higher in tissues from current smokers (n = 46) than in those from non-/former smokers (n = 24; 12.11 +/- 13.46 and 0.77 +/- 1.74 pmol/min/mg protein, respectively, mean +/- SD; P < 0.05). However, EROD activities in lung microsomes from current smokers CYP1A1*1/1 (n = 33) and heterozygous MspI variant CYP1A1*1/2A (n = 10) were not significantly different (12.23 +/- 13.48 and 8.23 +/- 9.76 pmol/min/mg protein, respectively, P > 0.05). Three current smokers were heterozygous variant CYP1A1*1/2B (possessing both *2A and *2C alleles), and exhibited activities similar to individuals CYP1A*1/1. One current smoker was heterozygous variant CYP1A1*4 and exhibited activities comparable with individuals CYP1A1*1/1 at that locus. EROD activities in microsomes from current smokers AHR(554)Arg/Arg (n = 41) and heterozygous variant AHR(554)Arg/Lys (n = 5) were not significantly different (12.13 +/- 13.56 and 12.01 +/- 14.23 pmol/min/mg protein, respectively; P > 0.05). Furthermore, microsomal EROD activities from current smokers with the GSTM1-null genotype (n = 28) were not significantly different from those (n = 18) carrying at least one copy of GSTM1 (12.61 +/- 14.24 and 11.34 +/- 12.53 pmol/min/mg protein, respectively; P > 0.05). Additionally, when genotypic combinations of CYP1A1, AHR, and GSTM1 were assessed, there were no significant effects on EROD activity. On the basis of microsomal enzyme activities from heterozygotes, CYP1A1*1/2A, CYP1A1*1/2B, CYP1A1*1/4, and AHR(554) Arg/Lys variants do not appear to significantly affect CYP1A1 activities in human lung, and we observed no association between CYP1A1 activity and the GSTM1-null polymorphism.     

Cytochrome P450 forms in the rodent lung involved in the metabolic activation of food-derived heterocyclic amines

The metabolic activation of the promutagens 2-amino-3,8-dimethylimidazo[4,5-f]quinoline(IQ), 2-amino-3,8-dimethyl-imidazo[4,5-f]quinoxaline (MeIQx)and 2-amino-1-methyI-6-phenylimidazo[4,5-b]pyridine (PhIP) byrat and mouse lung microsomes was studied using Salmonella mutagenicity(strain TA98). Lungs from uninduced animals were found to activateall three compounds. A 4–6 fold higher mutagenic activitywas obtained with IQ compared to MeIQx and the mutagenic responseof PhIP was 1–2 orders of magnitude lower than that ofIQ. In order to characterize the forms of P450 in the lung responsiblefor the metabolic activation of these food mutagens Westernblots were performed with microsomes and partially purifiedP450 fractions from the lung. Western blots revealed the presenceof cytochrome P450 2A, 2B and 4A forms in untreated rats. Inthe lung CYP 1A1 was only detectable after BNF treatment ofrats. The CYP 4A isozymes, which have not previously been describedin the rat lung, were further identified after PCR amplificationfrom lung mRNA as 4A2 and 4A8. Antibody inhibition studies showedthat CYP 2A3 catalyzed a major part (70%) of the metabolic activationof IQ by uninduced rat lung microsomes. The metabolic activationof MeIQx was not influenced by this antibody. An antibody againstCYP 2B isozymes also partially inhibited the activation of IQby uninduced rat lung microsomes. However, since induction ofCYP 2B isozymes in the liver by phenobarbital treatment didnot increase the metabolic activation of the heterocyclic aminesover controls it is unlikely that the rat lung CYP 2B1 is participatingin the activation of heterocyclic amines. The inhibition ofthe IQ-dependent mutagenicity by the CYP 2B antibody is probablydue to cross-reaction with CYP 2A3. Alfa-naptho-flavone (ANF),considered to be a specific inhibitor of CYP 1A isozymes at10 µM, partly inhibited the activation of IQ (30–40%)and MeIQx (60–80%) by uninduced rat and mouse lung microsomes.Upon pretreatment of rats with BNF, lung microsomes activatedMeIQx at a rate that was 2–10-fold higher than controllung microsomes, whereas the increase in EROD activity was approximately100-fold in the same lung preparations. These results suggestthat CYP 1A1 may not be the enzyme responsible for the activationof MeIQx in the control rat despite the inhibition with ANF.It is likely that ANF can inhibit other P450 enzymes in thelung, including CYP 2A3. The involvement of CYP 2A3. The involvementof CYP 2A3 in the metabolic activation of IQ by uninduced ratlung shows that CYP forms that are not of major importance inthe liver may play a significant role in extra-hepatic activationof heterocyclic amines.     

Lung cancer risk and CYP1A1 genotype in African Americans

The role of CYP1A1 genotype in lung cancer risk was assessed in African Americans through a case control study. The complete CYP1A1 genotype, including the frequency of all three polymorphisms (Msp1 [CYP1A1*2], exon 7 [CYP1A1*3] and African American specific [CYP1A1*4]) was determined by PCR on 307 controls and 105 cases of lung cancer among African Americans. We have confirmed our earlier observation of a significant increased risk (odds ratio = 2.8, 95% CI = 1.3-6.5) for lung adenocarcinoma among people with the *4 polymorphism, although we did not observe any association of this polymorphism with overall lung cancer risk. As previously reported, we found that lung adenocarcinoma patients with the *4 RFLP smoked significantly less than patients without this polymorphism, suggesting an important role in cancer risk of low exposure levels to cigarette smoke in subjects carrying susceptibility polymorphisms. There was no association with the other two polymorphisms and lung cancer in this population. When we examined lung cancer risk as a function of composite genotype, taking into account all three polymorphisms simultaneously in each subject, our preliminary data suggested an association of one rare genotype (homozygous Msp1, heterozygous exon 7 or *2/*2*3) with overall lung cancer risk (OR = 8.4, 95% CI = 1.6-43.2).